EQS Group-News: Medacta Group SA
/ Key word(s): Market launch
Media Release Medacta Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spine Pathologies The M.U.S.T. 2.0 system is the next generation of M.U.S.T. instruments that incorporates an upgraded geometrical design to support every single step of the surgery. A new innovation in material technology with the addition of a thin carbon film coating ensures superior instrument performance and durability thanks to wear-resistant properties. The M.U.S.T. 2.0 has been designed in collaboration with the Balgrist University Hospital in Zurich, Switzerland, thus being developed with an optimal insight in clinical experience together with an engineering foundation. After providing solid support to the design phase of the M.U.S.T. 2.0 system, Prof. Dr. med. Mazda Farshad, Medical Director, Chief of Orthopaedics and Chief of Division of Spine Surgery at the Balgrist University Hospital, has successfully accomplished the first series of spine surgeries with optimal initial outcomes. "The evolution of the M.U.S.T. spinal instrumentation was strongly driven by cognizant observations of each surgical step and incremental improvements. The M.U.S.T. 2.0 is a reliable system based on established concepts and innovations that simplify the surgical flow of spinal procedure," said Prof. Farshad. The M.U.S.T. 2.0 instrumentation is used to implant the Medacta M.U.S.T. (Medacta Universal Screw Technology) pedicle screw system, a universal polyaxial screw, rod and connector system applicable to degenerative, deformity and trauma cases. Medacta is continuing to deliver optimal solutions to surgeons for the benefit of their patients, and M.U.S.T. 2.0 represents a further expansion of the fast-growing Medacta spine portfolio.
For more information on the Medacta spine surgery solutions, please visit spine.medacta.com About Medacta
End of Media Release |
Language: | English |
Company: | Medacta Group SA |
Strada Regina | |
6874 Castel San Pietro | |
Switzerland | |
Phone: | +41 91 696 6060 |
E-mail: | info@medacta.ch,investor.relations@medacta.ch |
Internet: | www.medacta.com |
ISIN: | CH0468525222 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1140544 |
End of News | EQS Group News Service |
1140544 13.10.2020